# Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer

> **NCT03827044** · PHASE3 · TERMINATED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 30 (actual)

## Conditions studied

- POLE Exonuclease Mutant Colon Cancer
- Microsatellite Instability
- Stage III Colon Cancer

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03827044
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-31
- **Primary completion:** 2021-01-05
- **Final completion:** 2022-01-05
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** POLEM encountered significant recruitment challenges. With little prospect of recruiting to target the decision to close was made.
- **Last updated:** 2022-10-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03827044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03827044, "Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03827044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*